Columbia College of Physicians & Surgeons
Columbia Presbyterian (New York NY) - Urology
Mount Sinai Hospital (New York NY) - Minimally Invasive Oncology & Robotic Surgery
Yale-New Haven Hospital (New Haven CT) - Urologic Oncology
Clinical / Research Interests
Urologic Oncology
Prostate cancer including prostate MRI and MRI-ultrasound fusion biopsy
Bladder Cancer
Kidney Cancer
Testis cancer
Robotic Surgery with the DaVinci Si and Xi platforms

Michael J. Whalen, MD is Associate Professor of Urology at the George Washington University School of Medicine & Health Science. He graduated magna cum laude with a B.A. in Neurobiology from Harvard College and received his medical degree from Columbia College of Physicians & Surgeons in New York City. He completed his residency in Urology at New York Presbyterian Hospital-Columbia University Medical Center. Dr. Whalen has received fellowship training in Robotic and Minimally Invasive Urologic Oncology at Mount Sinai Hospital in New York and a completed a second fellowship in Urologic Oncology at Yale-New Haven Hospital. He is board-certified by the American Board of Urology and has been inducted as a member of the Society of Urologic Oncology.

Dr. Whalen’s specialty focus involves treatment of urological cancers, with expertise in both major open and minimally invasive surgery. His clinical interests include prostate cancer (including prostate MRI, MRI-ultrasound fusion biopsy and cryotherapy), bladder cancer (including blue-light cystoscopy and continent/incontinent urinary diversion), kidney cancer, testis cancer, adrenal cancer, ureteral cancer, robotic surgery with the DaVinci system (including prostatectomy, cystectomy, partial nephrectomy, and adrenalectomy) and laparoscopic surgery.

Dr. Whalen is actively involved in clinical outcomes research focusing on cancer of the prostate, bladder, and kidneys. He has published numerous original research articles in peer-reviewed journals, including Urologic OncologyUrology Practice, Prostate, Journal of Laparoendoscopic & Advanced Surgical Techniques, and BJU International. His research interests include robotic surgery techniques, optimization of pathologic reporting of urological cancers, and multiparametric magnetic resonance imaging (mp-MRI) and its role in prostate cancer management—active surveillance, post-treatment biochemical recurrence, focal ablation, and comparison to/integration with commercially-available serum-based and tissue-based genomic assays.

Dr. Whalen has presented at numerous conferences in the US and internationally, including the American Urological Association (AUA) National Conference, the AUA New York Section Ferdinand C. Valentine Medal & Resident Essay Meeting, the 2016 World Cancer Congress in Shanghai, China, and the 2014 AUA National Chief’s Debate, which he won as a representative of the New York Section. He is a member of the American Urological Association and serves on the Editorial Board of the ARC Journal of Urology (AJU), as a reviewer for Current Urology, and as a reviewer/statistical consultant for the Journal of Urology.

​Dr. Whalen's recent book chapter on Preventing Erectile Dysfunction after Radical Prostatectomy can be viewed by clicking here.

Washingtonian 2020 Top Doctors plaque

Dr. Whalen has been recognized as one of Washingtonian's 2020 Top Doctors.

Dr. Whalen honored by Marquis Who's Who

Dr. Michael Whalen selected as Top Urologist of the Year by the International Association of Top Professionals (IAOTP).

abc logo
cbs logo
CW logo
FOX logo
NBC logo


Listen to Dr. Michael Whalen's podcast regarding how to lower your risk of prostate cancer. Press the play button below:     

What the New Prostate Screening Guidelines Mean for Men’s Health:

Radio Interviews


  1. An integrative active surveillance of prostate cancer. Marisa Dunn, Danielle Mirda, Michael Whalen, Mikhail Kogan. Explore: The Journal of Science & Healing. (accepted for publication 4/12/21).
  2. Use of the T-1470 LiteTouch™ Laser in the En Bloc Resection of an Upper Tract Urothelial Cancer," Ezra Shoen, Benjamin Zollinger, Tripp Gresham, Katayoon Rezaei, Michael Whalen. Case Reports in Urology, vol. 2021, 1/27/21. (Article ID 6623326)
  3. Trends in treatment strategies and comparisons of outcomes in lymph node positive bladder cancer: An Analysis of the National Cancer Database. Christina Darwish, Andrew Sparks, Richard Amdur, Michael Whalen. Urology, 2020; 146:168-176.
  4. Applications and Outcomes in Urologic Oncology: Prostate, Kidney, and Penile Cancer. Understanding Cryotherapy, Ben Molvig (Ed.). Nova Science Publishers, Inc. New York: 2020
  5. Peri-operative Venous Thromboembolism Prophylaxis in Urological Surgery: Why & How? (BJUI Knowledge Online Learning Module) Michael J. Whalen, Charles Gresham, Ketan K. Badani. Revised 9/2019; originally published online 7/2017.
  6. Trends in the use of Neoadjuvant Chemotherapy for Bladder Cancer with Non-Urothelial and Variant Histology: An analysis of the National Cancer Database (NCDB). Campbell Grant, Andrew Sparks, Richard Amdur, Michael Whalen. Ind J Urol, 2019. 35(4):291-298
  7. Preventing Erectile Dysfunction after Radical Prostatectomy: Nerve-Sparing Techniques, Penile Rehabilitation, and Novel Regenerative Therapies. Michael Whalen. Prostatectomy, Tsvetin Genadiev, IntechOpen, November 5th 2018. DOI: 10.5772/intechopen.79398.
  8. Lymph node yield during radical prostatectomy does not impact rate of biochemical recurrence in patients with seminal vesicle invasion and node-negative disease. Badani KK, Reddy, BN, Moskowitz EJ, Paulucci DJ, Beksac AT, Martini A, Whalen MJ, Skarecky DW, Huynh LM, Ahlering TE. Urol Oncol, 2018; 36(6): 310e1-310e6.
  9. Oncologic Outcomes of Different Definitive Treatments of Prostate Cancer after a Period of Active Surveillance. Michael J. Whalen, Jamie S. Pak, Danny Lascano David Ahlborn, Justin T. Matulay, James. M. McKiernan. Clin Genitourin Cancer, 2018; 16(2): e425-35
  10. Current evidence for active surveillance for intermediate risk prostate cancer: editorial on comparison of pathological and oncologic outcomes in "favorable risk" GS 3+4 and low risk GS6 prostate cancer by Gearman et al., Journal of Urology. Gordhan C & Whalen MJ. AME Med J, 2018; 3(55): 1-5.
  11. Does the number of lymph nodes sampled during radical prostatectomy impact risk of biochemical recurrence in patients with isolated seminal vesicle invasion? Mark Silva, Michael J. Whalen, Michael Rothberg, Edan Y. Shapiro, Trushar Patel, Ari Bergman, Arindam RoyChoudhury, James McKiernan, Mitchell C. Benson, Ketan K. Badani. ARC J Urol, 2016; 1(1): 1-7.
  12. Use of Partial Nephrectomy After Acquisition of a Surgical Robot: A Population-Based Study. Aaron C. Weinberg, Jason D. Wright, Michael J. Whalen, Solomon L. Woldu, Stephanie A. Berger, Christopher M. Deibert, Ruslan Korets, Dawn L. Hershman, Alfred I. Neugut, and Ketan K. Badani. Urol Prac, 2016; 3(6): 430-436
  13. Prospective Correlation between Probability of Favorable Pathology on the 17-gene Genomic Prostate Score and Actual Pathologic Outcomes at Radical Prostatectomy. Michael J. Whalen, James M. McKiernan, Mitchell C. Benson, and Ketan K. Badani. Urol Prac, 2016. 3:1-8
  14. Testosterone replacement therapy in men with prostate cancer. Michael J. Whalen. J Urol Res, 2016; 3(2): 1051.
  15. Pathologic Reporting of the Surgical Margin after Radical Prostatectomy: Considerations for Improving Oncologic Prognostication. Michael J. Whalen & Michael B. Rothberg. Int J Path Clin Res, 2016. 2(1): 1-7.
  16. Predictors of Biochemical Recurrence in pT3b Prostate Cancer after Radical Prostatectomy without Adjuvant Radiotherapy. Matthew J. Pagano, Michael J. Whalen, David J. Paulucci, Balaji N. Reddy, Justin T. Matulay, Michael Rothberg, Edan Y. Shapiro, Kyle Scarberry, Arindam RoyChoudhury, James McKiernan, Mitchell C. Benson, Ketan K. Badani. Prostate, 2016; 76(2): 226-34.
  17. Partial Cystectomy for Primary Bladder Tumors, in Contemporary Patients with Diverse Tumor Locations. Matthew R. Danzig, BS; Ari R. Berg, BS; Rashed A. Ghandour, MD; Danny Lascano, BS; Michael J. Whalen, MD; Mitchell C. Benson, MD; G. Joel DeCastro, MD, MPH; James M. McKiernan, MD. Urol Practice, 2016. 3(1): 55-61
  18. Utilization of the Robotic Surgical Platform for Radical Nephrectomy: A National Comparison of Trends for Open, Laparoscopic, and Robotic Approaches. Aaron C. Weinberg, Michael J. Whalen, David J. Paulucci, Solomon Woldu, Christopher M. Deibert, Ruslan Korets and Ketan K. Badani. Urol Practice, 2016; 3(3): 187-194.
  19. Analysis of the Transperitoneal Approach to Robot-Assisted Laparoscopic Partial Nephrectomy for Treatment of Anterior and Posterior Renal Masses. David J. Paulucci, Michael J. Whalen, Ketan K. Badani. J Laparoendosc Adv Surg Tech A, 2015; 25(11): 880-5
  20. Close Surgical Margins after Radical Prostatectomy Mimic Biochemical Recurrence Rates of Positive Margins. Michael J. Whalen, Edan Y. Shapiro, William T. Berg, Michael B. Rothberg, Solomon L. Woldu, Arindam RoyChoudhury, Ari Bergman, Trushar Patel, Ketan K. Badani (Urol Oncol, 2015; 33:494.e9-e15.
  21. Utilization and perioperative outcomes of partial cystectomy for urothelial carcinoma of the bladder: Lessons from the ACS-NSQIP database. Michael J. Whalen, Matthew R. Danzig, Jamie S. Pak, Blake D. Alberts, Ketan K. Badani, G. Joel DeCastro, James M. McKiernan. Urol Practice, 2015; 2(3): 109-114.
  22. Lessons learned from routine intraoperative ureteral margin frozen sections during radical cystectomy. Michael J. Whalen, Jamie Lynn RiChard, Rashed Ghandour, Michael Lipsky, Michael Piecuch, Mitchell C. Benson, Alan M. Nieder, G. Joel DeCastro, James M. McKiernan. Urol Practice, 2015; 2(2): 90-95
  23. Getting More Selective about Partial Nephrectomy. Michael J. Whalen, Ardeshir R. Rastinehad, Ketan K. Badani. AUA News, 2015; 20(3): 7, 27-28.
  24. Selective arterial clamping does not improve outcomes in robot‐assisted partial nephrectomy: a propensity‐score analysis of patients without impaired renal function. David J. Paulucci Daniel C. Rosen John P. Sfakianos Michael J. Whalen Ronney Abaza Daniel D. Eun Louis S. Krane Ashok K. Hemal Ketan K. Badani. BJU Int, 2016; 119(3): 430-435.
  25. Fournier’s Gangrene. Case report. Matilsky D, Lewiss R, Whalen M, Saul T. Med Ultrason, 2014; 16(3): 1-2.
  26. Neoadjuvant chemotherapy in the treatment of muscle invasive bladder cancer with mixed histology. James Lin, Michael Whalen, Dara Holder, G. Joel DeCastro, Greg Hruby, James McKiernan. Can J Urol, 2013. 20(2): 6690-5.
  27. Associated conditions of the prepuce: phimosis, concealed penis, and penile torsion. Gina M. Badalato, Marc Holden, Michael Whalen, and Grace Hyun. Chapter in Pediatric Urology Book. Wilcox, Godbole, Cooper, eds.
  28. The Effect of Race and Gender on the Surgical Management of the Small Renal Mass. Max Kates, Michael J. Whalen, Gina M. Badalato, James M. McKiernan. Urol Oncol, 6/2012

Past Articles

Articles from 2020


Clinical Trials

Primary objective to compare overall survival in metastatic prostate cancer patients who are randomized to standard systemic therapy (SST) plus definitive treatment of the primary tumor versus standard systemic therapy alone.